ProQR Therapeutics N.V. (NASDAQ:PRQR) traded today at a new 52-week high of $8.88. So far today approximately 3.4 million shares have been exchanged, as compared to an average 30-day volume of 531,000 shares.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber’s congenital amaurosis type 10 and dyastrophic epidermolysis bullosa. The company’s main product candidates are QR-010, QR-110, and QR-313. Its product pipeline includes QRX-704, QRX-504, QRX-421, QRX-323 etc.
ProQR Therapeutics N.V. (NASDAQ:PRQR) is currently priced 22.7% above its average consensus analyst price target of $5.76.
Over the past year, ProQR Therapeutics N.V. has traded in a range of $3.40 to $8.88 and is now at $7.46, 119% above that low.
Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected
About InvestorBrandNetwork (IBN)
InvestorBrandNetwork (IBN) consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer